Sugi Predict

Sugi Predict / Compounds / Cetefloxacin

Cetefloxacin

Cetefloxacin

SCHEMBL1230055

C[C@H]1[C@H](N)CN1c1cc2c(cc1F)c(=O)c(C(=O)O)cn2-c1ccc(F)cc1F

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHA2 P29317 1/20 0.54
▸ FLT4 P35916 1/20 0.54
▸ GSK3B P49841 1/20 0.54
▸ RARB P10826 1/20 0.54
▸ TBXAS1 P24557 1/20 0.54
▸ SLC6A3 Q01959 1/20 0.54
▸ KMT2A Q03164 2/20 0.53
▸ ALDH1A1 P00352 7/20 0.52
▸ LMNA P02545 6/20 0.52
▸ KDM4E B2RXH2 6/20 0.52
▸ HPGD P15428 5/20 0.52
▸ HSD17B10 Q99714 5/20 0.52
▸ HTT P42858 2/20 0.52
▸ POLB P06746 1/20 0.52
▸ XBP1 P17861 1/20 0.52
▸ NFKB1 P19838 1/20 0.52
▸ NFKB2 Q00653 1/20 0.52
▸ RELA Q04206 1/20 0.52
▸ MEN1 O00255 1/20 0.52
▸ TOP1 P11387 4/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cetefloxacin SCHEMBL9147898 1.00 EPHA2 (0.54) EPHA2FLT4GSK3BRARBTBXAS1
Cetefloxacin SCHEMBL9147891 1.00 EPHA2 (0.54) EPHA2FLT4GSK3BRARBTBXAS1
SCHEMBL9147269 0.90 LMNA (0.64) EPHA2FLT4GSK3BRARBTBXAS1
SCHEMBL9147249 0.90 LMNA (0.64) EPHA2FLT4GSK3BRARBTBXAS1
SCHEMBL9147260 0.90 LMNA (0.64) EPHA2FLT4GSK3BRARBTBXAS1
SCHEMBL9210974 0.89 GSK3B (0.43) EPHA2FLT4GSK3BRARBTBXAS1
SCHEMBL9043188 0.87 KMT2A (0.54) EPHA2FLT4GSK3BRARBTBXAS1
SCHEMBL10514084 0.87 KMT2A (0.54) EPHA2FLT4GSK3BRARBTBXAS1
SCHEMBL10665291 0.86 EPHA2 (0.56) EPHA2FLT4GSK3BRARBTBXAS1
SCHEMBL9145569 0.85 EPHA2 (0.53) EPHA2FLT4GSK3BRARBTBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2961730-A2 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XenoPort, Inc. (US) 2016-01-06 — — EP claimed
US-20150158809-A9 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2015-06-11 — — US claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
WO-2014134005-A2 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2014-09-04 — — WO claimed
US-20140243544-A1 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2014-08-28 — — US claimed
CN-101486668-B Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof XENOPORT INC 2014-07-02 — — CN claimed
US-8299291-B2 Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs XENOPORT, INC. (US) 2012-10-30 — — US claimed
US-8062870-B2 Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs XENOPORT, INC. (US) 2011-11-22 — — US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
EP-0388298-B1 Derivatives of pyridone carboxylic acids substituted by an azetidine, their preparation and their use as medicines ESTEVE LABOR DR (ES) 1995-06-21 — — EP claimed
JP-6025224-A — — None — — JP disclosed
EP-3782649-B1 BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS ASCENDIS PHARMA AS (DK) 2025-05-14 — — EP disclosed
US-20230381323-A1 RELEASABLE CONJUGATES FISH & RICHARDSON PC 2023-11-30 — — US disclosed
US-20050222431-A1 Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof XENOPORT, INC. 2005-10-06 — — US disclosed
WO-2005066122-A2 SYNTHESIS OF ACYLOXYALKYL CARBAMATE PRODRUGS AND INTERMEDIATES THEREOF XENOPORT, INC. (US) 2005-07-21 — — WO disclosed
US-5393758-A Bactericides, microbiocides LABORATORIOS DEL DR. ESTEVE S.A. (ES) 1995-02-28 — — US disclosed
JP-H0625224-A NEW PYRIDONECARBOXYLIC ACID AZETIDINE DERIVATIVE HAVING ANTIMICROBIAL ACTIVITY LAB DEL DR ESTEVE SA 1994-02-01 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222431-A1 Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof CPS1, ACMSD, NAAA EPHA2 4469/4885FLT4 2010/4885GSK3B 3008/4885
US-20150158809-A9 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS CPS1, CA7, NAAA EPHA2 4580/4885FLT4 1682/4885GSK3B 3111/4885
US-20230381323-A1 RELEASABLE CONJUGATES GUSB, ABCB11, UGT2B7 EPHA2 383/4885FLT4 2670/4885GSK3B 2400/4885
US-20140243544-A1 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS CPS1, CA7, NAAA EPHA2 4580/4885FLT4 1682/4885GSK3B 3111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback